Atreca's - BCEL market analysis on 18th September 2020

Transaction Date	Recipient	Shares	Type	Price	Value
9th September 2020	Group, Llc Redmile	8,650	Open or private purchase	$51.85	$448,523.26
9th September 2020	Group, Llc Redmile	14,610	Open or private purchase	$52.96	$773,811.35
8th September 2020	Bros. Advisors Lp Baker	6,151	Open or private purchase	$47.39	$291,479.90
8th September 2020	Bros. Advisors Lp Baker	15,172	Open or private purchase	$47.47	$720,199.67
8th September 2020	Bros. Advisors Lp Baker	15,807	Open or private purchase	$47.04	$743,482.25
8th September 2020	Bros. Advisors Lp Baker	76,473	Open or private purchase	$47.39	$3,623,856.64
8th September 2020	Bros. Advisors Lp Baker	1,220	Open or private purchase	$47.47	$57,912.18
8th September 2020	Bros. Advisors Lp Baker	185	Open or private purchase	$45.88	$8,486.88
8th September 2020	Group, Llc Redmile	47,113	Open or private purchase	$49.91	$2,351,504.06
8th September 2020	Bros. Advisors Lp Baker	1,272	Open or private purchase	$47.04	$59,828.52

Atreca

Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients.

Ticker: BCEL

Sector: Health Technology

Industry: Biotechnology

SEC Central Index Key (CIK): 1532346

Employees: 113

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis